Quantcast
Home > Quotes > VTGN

VistaGen Therapeutics, Inc. Common Stock (VTGN) Quote & Summary Data

VTGN 
$0.51
*  
0.0145
2.93%
Get VTGN Alerts
*Delayed - data as of Aug. 16, 2019  -  Find a broker to begin trading VTGN now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
1 Year Target
2.35
Today's High / Low
$ 0.53 / $ 0.4955
Share Volume
190,627
50 Day Avg. Daily Volume
195,006
Previous Close
$ 0.4955
52 Week High / Low
$ 2.44 / $ 0.3801
Market Cap
21,737,712
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
1.1

Intraday Chart

Shares Traded

Share Volume:
190,627
50 Day Avg. Daily Volume:
195,006

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -0.93

Trading Range

The current last sale of $0.51 is 34.18% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 0.53 $ 2.44
 Low: $ 0.4955 $ 0.3801

Company Description (as filed with the SEC)

We are a clinical-stage biopharmaceutical company committed to developing and commercializing new generation medicines to treat diseases and disorders of the central nervous system (CNS) with high unmet need. Our portfolio of three clinical-stage product candidates is currently focused on major depressive disorder (MDD), neuropathic pain (NP), levodopa-induced dyskinesia (LID), social anxiety disorder (SAD) and suicidal ideation (SI). Our most advanced product candidate, PH94B neuroactive nasal spray, is fundamentally different from all current treatments for SAD. Developed from proprietary compounds called pherines and administered as a nasal spray, PH94B activates nasal chemosensory receptors that trigger neural circuits in the brain that suppress fear and anxiety.  ... More ...  



Risk Grade

Where does VTGN fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 0.498
Open Date:
Aug. 16, 2019
Close Price:
$ 0.51
Close Date:
Aug. 16, 2019


Consensus Recommendation

Analyst Info